I read the 8K, that damn thing was cheap at $92! Those gaap earnings are solid. I wish I had looked at it when you called it out. I blew it off because I thought the tariffs would hurt it. I bet a lot of shorts got hammered bad on this one.
Dear Stoney- Well you really showed me how to use metal names today. I bought your ASM silver idea at about $2.40 on the open and now it is $2.60 up 14%. In one day. I am humbled by your brilliance. - NINE
I see I gave the wrong symbol up above-- Watching-->NEXN Nexxen International Ltd. $11.88 0.26(+2.24%)11:44 AM 05/15/25 NASDAQ |$USD |Realtime
I don't know what's more surprising, that FreshPet trades for $80+ or that JANA boys want a piece pf it... JANA Partners takes stake in Freshpet, exits position in Wolfspeed » 12:30 FRPT
SSR Mining price target raised by C$1 at Canaccord » 12:10 SSRM STOCK OF THE DAY***** Organon and Co call volume above normal and directionally bullish » 12:05 OGN Organon projects over $1B in Nexplanon revenue for 2025 amid continued expansion Thu, May 01 MAY 9 CEO & Director of Organon Picks Up 14% More Stock
Potential Organon & Co.(NYSE:OGN) shareholders may wish to note that the CEO & Director, Kevin Ali, recently bought US$299k worth of stock, paying US$8.81 for each share. That's a very solid buy in our book, and increased their holding by a noteworthy 14%.
PE 2? EPS $3.83 WTF OGN Organon & Co. 1 YEAR DOWN 58%!! $8.80 0.76(+9.45%)12:47 PM 05/15/25 NYSE |$USD |Realtime Company Profile Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.